Filing Details

Accession Number:
0001209191-12-045604
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-09-14 17:06:43
Reporting Period:
2012-09-12
Filing Date:
2012-09-14
Accepted Time:
2012-09-14 17:06:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1472595 Accretive Health Inc. AH Services-Management Services (8741) 020698101
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1200675 Jr Edgar Bronfman C/O Accretive Health, Inc.
401 North Michigan Avenue, Suite 2700
Chicago IL 60611
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2012-09-12 40,300 $13.16 473,483 No 4 S Indirect Refer to footnote
Common Stock Disposition 2012-09-13 209,700 $12.16 263,783 No 4 S Indirect Refer to footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Refer to footnote
No 4 S Indirect Refer to footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,156,092 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.44, inclusive. The reporting person undertakes to provide to Accretive Health, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
  2. Represents shares of common stock of the Issuer held by Lexa Partners II LLC ("Lexa Partners"). Trusts and custodians for the benefit of the children of the Reporting Person are members of Lexa Partners. The Reporting Person is not a member of Lexa Partners nor a trustee or custodian of the members of Lexa Partners, and the Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the common stock held by Lexa Partners.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.88, inclusive.